New combination promising against colon cancer.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068579:Celecoxib; D003110:Colonic Neoplasms / Q000188:drug therapy*; D051546:Cyclooxygenase 2; D004357:Drug Synergism; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D051379:Mice; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D013449:Sulfonamides / Q000627:therapeutic use*; D000068878:Trastuzumab; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D007527:Isoenzymes; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D018719:Erb-b2 Receptor Tyrosine Kinases; D013449:Sulfonamides; D000068878:Trastuzumab